Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalisation in Patients With COVID-19

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalisation in Patients With COVID-19

Background: Efficient healthcare based on prognostic variables in hospitalised patients with COVID-19 could reduce the risk of complications and death. Recently, soluble urokinase Plasminogen Activator Receptor (suPAR) was shown to predict respiratory failure, kidney injury, and clinical outcome in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Helena Enocsson, Cornelia Idoff, Annette Gustafsson, Melissa Govender, Francis Hopkins, Marie Larsson, Åsa Nilsdotter-Augustinsson, Johanna Sjöwall
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
suPAR
COVID-19
biomarker
disease severity
respiratory failure
length of hospital stay
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/a986ea9b787f4045a1f4051395375ba9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/a986ea9b787f4045a1f4051395375ba9

Ejemplares similares